Scientists reverse heart failure via newly discovered regeneration pathway

human heart
The signaling pathway called Hippo may be able to be altered to promote heart regeneration, scientists have found.

A signaling pathway in the body called Hippo is well known in scientific circles for its potential role in cancer, but now scientists at Baylor believe they have found another place where manipulating this system could be beneficial—the heart.

Hippo signaling can prevent damaged heart muscle from repairing itself. So the Baylor researchers wanted to see what would happen if they turned off the pathway altogether. When they silenced Hippo for 6 weeks in mouse models of heart failure, they were able to restore pumping ability to that of healthy hearts, according to a press release. The research was published in the journal Nature.

RELATED: Merck KGaA steps up Hippo pathway cancer pact with CRT


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Because blood flow stops during a heart attack, muscle tissue can die. That dead muscle is replaced by scar tissue that’s unable to help the heart to pump. Over time, the heart continues to weaken, leading to chronic heart failure in most people. The Baylor team recognized that Hippo signaling activity increases during a heart attack, suggesting a link between the pathway and the heart’s inability to repair itself.

The effort to find new ways of combating heart disease is largely aimed at promoting regeneration of damaged heart muscle. In May, Japanese scientists identified a signaling protein called urocortin2 (Ucn2) that’s elevated in people with chronic heart failure. When they used this protein to silence another protein called corticotropin-releasing hormone receptor 2 (Crhr2), they were able to prevent the loss of cardiac function in mouse models.

Cell therapy is also a potential treatment for heart failure. In the spring, Australian biotech company Mesoblast released positive data from a trial of mesenchymal precursor cells (MPCs) that are delivered straight into the left ventricular muscle of heart failure patients. Several other companies are investigating different cell-based approaches to promoting heart regeneration.

RELATED: Vivace uncloaks with $40M, U.S.-China backing for cancer trials

The scientists at Baylor have a theory about why inhibiting the Hippo pathway might prove to be an effective regenerative therapy: It seems to alter the abnormal thickening of the heart muscle, or “fibrosis,” that is seen in heart failure, in addition to encouraging cardiac muscle cells to grow and survive in injured hearts. The team plans further studies to shed light on how inhibiting Hippo affects fibrosis.

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.